

(19) 世界知的所有権機関
国際事務局



(43) 国際公開日
2004 年10 月21 日 (21.10.2004)

PCT

(10) 国際公開番号
WO 2004/090541 A1

(51) 国際特許分類⁷: G01N 33/53,
33/50, 33/15, A61K 45/00, 31/353, A61P 9/00, 9/10,
25/00, 25/28, 35/00, 37/08

(21) 国際出願番号: PCT/JP2004/004772

(22) 国際出願日: 2004 年4 月1 日 (01.04.2004)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:
特願2003-097652 2003 年4 月1 日 (01.04.2003) JP

(71) 出願人 (米国を除く全ての指定国について): 三菱
ウェルファーマ株式会社 (MITSUBISHI PHARMA
CORPORATION) [JP/JP]; 〒5410046 大阪府大阪市
中央区平野町二丁目 6 番 9 号 Osaka (JP).

(71) 出願人 および

(72) 発明者: 立花 宏文 (TACHIBANA, Hirofumi) [JP/JP];
〒8130016 福岡県福岡市東区香椎浜四丁目 7 番 8 号
Fukuoka (JP).

(74) 代理人: 高柳 昌生 (TAKAYANAGI, Masau); 〒1038405
東京都中央区日本橋本町二丁目 2 番 6 号三菱ウェル
ファーマ株式会社 知的財産部 Tokyo (JP).

(81) 指定国 (表示のない限り、全ての種類の国内保護が
可能): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) 指定国 (表示のない限り、全ての種類の広域保護が
可能): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL,
SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM), ヨーロッパ (AT, BE, BG, CH, CY,
CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

添付公開書類:
— 国際調査報告書

2 文字コード及び他の略語については、定期発行される
各PCTガゼットの巻頭に掲載されている「コードと略語
のガイダンスノート」を参照。

(54) Title: METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY

(54) 発明の名称: 67 kDa ラミニン・レセプターを用いた薬物のスクリーニング方法及びそれにより得られる薬物

(57) Abstract: It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiarteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiarteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.

(57) 要約: 67 kDa ラミニン・レセプターを用いた薬物の新規なスクリーニング方法及びそれにより得られる薬物を提供する。被験化合物と67 kDa ラミニン・レセプターとの結合の度合いを定性的または定量的に測定し、その測定結果より被験化合物が67 kDa ラミニン・レセプターに結合する場合にはその被験化合物が細胞増殖抑制作用、血管新生阻害作用、癌細胞の転位活性阻害作用、神経保護作用、抗アレルギー作用、抗動脈硬化作用、及び/または、クロイツフェルトヤコブ病感染阻害作用を有する薬物であると判断する工程を含む、細胞増殖抑制作用、血管新生阻害作用、癌細胞の転位活性阻害作用、神経保護作用、抗アレルギー作用、抗動脈硬化作用、及び/または、クロイツフェルトヤコブ病感染阻害作用を有する薬物のスクリーニング方法、並びに、それにより得られる薬物。

WO 2004/090541 A1

名義変更届

特許庁長官 殿

1. 国際出願の表示 PCT/J P 2004/004772

2. 出願人

名 称 株式会社産学連携機構九州
KYUSHU TLO COMPANY, LIMITED
あて名 〒812-8581 日本国福岡県福岡市東区箱崎6丁目10番1号
10-1, Hakozaki 6-chome, Higashi-ku, Fukuoka-shi, Fukuoka 812-8581
Japan
国 籍 日本国 JAPAN
住 所 日本国 JAPAN

3. 届け出の内容 新名義人

事件との関係 米国及び日本を除く全ての指定国における出願人
名 称 株式会社産学連携機構九州
KYUSHU TLO COMPANY, LIMITED
あて名 〒812-8581 日本国福岡県福岡市東区箱崎6丁目10番1号
10-1, Hakozaki 6-chome, Higashi-ku, Fukuoka-shi, Fukuoka 812-8581
Japan
国 籍 日本国 JAPAN
住 所 日本国 JAPAN

事件との関係 指定国日本における出願人
名 称 三菱ウェルファーマ株式会社
MITSUBISHI PHARMA CORPORATION
あて名 〒541-0046 日本国大阪府大阪市中央区平野町二丁目6番9号
6-9, Hiranomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-0046
Japan
国 籍 日本国 JAPAN
住 所 日本国 JAPAN

事件との関係 指定国米国及び日本における出願人及び全ての指定国における発明者
氏 名 立花 宏文
TACHIBANA Hirofumi
あて名 〒813-0016 日本国福岡県福岡市東区香椎浜四丁目7番8号
7-8, Kashiihama 4-chome, Higashi-ku, Fukuoka-shi, Fukuoka 813-0016
Japan
国 籍 日本国 JAPAN
住 所 日本国 JAPAN

4. 添付書類の目録 (1) 譲渡証書 2通

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/004772

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ G01N33/53, G01N33/50, G01N33/15, A61K45/00, A61K31/353,
A61P9/00, A61P9/10, A61P25/00, A61P25/28, A61P35/00, A61P37/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ G01N33/53, G01N33/50, G01N33/15, A61K45/00, A61K31/353,
A61P9/00, A61P9/10, A61P25/00, A61P25/28, A61P35/00, A61P37/08

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Toroku Jitsuyo Shinan Koho 1994-2004
Kokai Jitsuyo Shinan Koho 1971-2004 Jitsuyo Shinan Toroku Koho 1996-2004

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
BIOSIS (DIALOG), WPI (DIALOG), JICST (JOIS), CA (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X/A	WO 99/54356 A (THE QUEEN'S UNIVERSITY OF BELFAST), 28 October, 1999 (28.10.99), Full text & EP 1073679 A	1, 2/ 4-6, 12-17, 25-30
X	JP 2000-226329 A (Meiji Milk Products Co., Ltd.), 15 August, 2000 (15.08.00), Claims (Family: none)	25-30
X	JP 2002-220340 A (Ito En, Ltd.), 09 August, 2002 (09.08.02), Claims; Par. Nos. [0005], [0020], [0021] (Family: none)	25-30

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
18 May, 2004 (18.05.04)

Date of mailing of the international search report
01 June, 2004 (01.06.04)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/004772

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 2001-114687 A (Mitsui Norin Co., Ltd.), 24 April, 2001 (24.04.01), Par. No. [0003] (Family: none)	25-30
P, X	TACHIBANA "A receptor for green tea polyphenol EGCG.", Nat.Struct.Mol.Biol., Vol.11, No.4, (2004) pages 380 to 381	1-30
A	JP 8-205885 A (La Jolla Cancer Research Foundation), 13 August, 1996 (13.08.96), & JP 3-504383 A & WO 89/11273 A & EP 452314 A & US 5180809 A	1-30
A	JP 6-219965 A (The United States of America), 09 August, 1994 (09.08.94), & JP 60-500974 A & WO 84/03946 A & US 4565789 A	1-30

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/004772

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 3, 7-11, 18-24
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
(See extra sheet.)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/004772

Continuation of Box No.II-2 of continuation of first sheet (2)

Claims 3, 7 to 11 and 18 to 24 relate to so-called screening method-specified compounds or compounds specified exclusively by a function and, therefore, it is completely unknown what specific compounds are involved therein and what are not. Thus, these claims are described in an extremely unclear manner.